By Paul Baas, MD, PhD, and Cornedine J. de Gooijer, MD Posted: June 24, 2020 Recently, a manuscript by Ceresoli et al. was published in The Lancet Oncology.1 The study […] Read more
PROVIDER RESOURCES
MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC
INDUSTRY SUPPORTED
COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events